[18F] fluromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: A feasibility study

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Gagel, Bernd ^a   Reinartz, Patrick ^a   Demirel, Cengiz ^a   Kaiser, Hans J ^a   Zimny, Michael ^a   Piroth, Marc ^a   Pinkawa, Michael ^a   Stanzel, Sven ^a   Asadpour, Branka ^a   Hamacher, Kurt ^b   Coenen, Heinz H ^b   Buell, Ulrich ^a   Eble, Michael J ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ECAT EXACT 922/47; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; NAVELBINE; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GLUCOSE; MISONIDAZOLE; RADIOPHARMACEUTICAL AGENT; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CAUSE OF DEATH; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; HEART ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; HYPERTHYROIDISM; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; KIDNEY METASTASIS; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SCINTISCANNING; LYMPH NODE METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MEDIASTINUM LYMPH NODE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; TISSUE OXYGENATION; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR RECURRENCE; VALIDATION PROCESS; VIRUS PNEUMONIA; CELL HYPOXIA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PROSPECTIVE STUDY; SCINTISCANNING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARRHYTHMIAS, CARDIAC; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MISONIDAZOLE; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; VINBLASTINE;

EID: 33646241326     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-51     Document Type: Article

References (25)

1. Chaiken L, Rege S, Hoh C, Choi Y, Jabour B, Juillard G, Hawkins R, Parker R: Positron emission tomography with fluorodeoxyglucose to evaluate tumour response and control after radiation therapy. Int J Radiat Oncol Biol Phys 1993, 27:455-464.
2. Chapman JD, Schneider RF, Urbain JL, Hanks GE: Single-photon emission computed tomography assays for tissue oxygenation. Semin Radiat Oncol 2001, 11:47-57.
3. 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial. J Clin Oncol 2003, 21:428-432.
4. Dunst J, Stadler P, Becker A, Lautenschlager C, Pelz T, Hansgen G, Molls M, Kuhnt T: Tumour volume and tumour hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 2003, 179:521-526.
5. 18F-Misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005, 46:253-260.
6. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, Pratt B, Husband J, Flower M, Ott R: Noninvasive monitoring of tumour metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumour response to fluorouracil. J Clin Oncol 1996, 14:700-708.
7. 18F]-2-fluoro-2′-deoxyglucose): an appraisal of radiotherapeutic relevant hypoxia. Strahlenther Onkol 2004, 180:616-622.
8. Gray LH, Conger AD, Ebert M: The concentration of oxygen dissolved in tissue at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953, 26:638-642.
9. Höckel M, Schleger K, Aral B, Mitze M, Schaffer U, Vaupel P: Association between tumour hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56:4509-4515.
10. Kirkpatrick JP, Cardenas-Navia LI, Dewhirst MW: Predicting the effect of temporal variations in PO2 on tumor radiosensitivity. Int J Radiat Oncol Biol Phys 2004, 59:822-833.
11. Ling CC, Yorke E, Amols H, Mechalakos J, Erdi Y, Leibel S, Rosenzweig K, Jackson A: High-tech will improve radiotherapy of NSCLC: A hypothesis waiting to be validated. Int J Radiat Oncol Biol Phys 2004, 60:3-7.
12. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, Ball DL: Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003, 21:1285-1292.
13. Minn H, Kangas L, Knuutila V, Paul R, Sipila H: Determination of 2-fluoro-2-deoxy-D-glucose uptake and ATP level for evaluating drug effects in neoplastic cells. Res Exp Med 1991, 191:27-35.
14. Misquitta A, Herman S, Winton T: Accuracy of CT in predicting prognosis in patients with non-small cell lung carcinoma after induction chemotherapy [abstract]. Radiology 1994, 193:257.
15. Nagata Y, Yamamoto K, Hiraoka M, Abe M, Takahashi M, Akuta K, Nishimura Y, Jo S, Masunaga S, Kubo S: Monitoring liver tumour therapy with 18[F]FDG positron emission tomography. J Comput Assist Tomogr 1990, 14:370-374.
16. Nunn A, Linder K, Strauss HW: Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995, 22:265-280.
17. Overgaard J, Horsman M: Modification of hypoxia-induced radio resistance in tumours by the use of oxygen and sensitizers. Semin Radiat Oncol 1996, 6:10-21.
18. Price P, Jones T: Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer 1995, 31A:1924-1927.
19. Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA: Radio-labelled fluoromisonidazole as an imaging agent for tumour hypoxia. Int J Radiat Oncol Biol Phys 1989, 17:985-991.
20. Reisser C, Haberkorn U, Dimitrakopoulou-Strauss A, Seifert E, Strauss LG: Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch Otolaryngol 1995, 121:272-276.
21. Schäfer U, Micke O, Müller SB, Schuller P, Willich N: Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 2003, 179:527-534.
22. Stuben G, Pottgen C, Knuhmann K, Schmidt K, Stuschke M, Thews O, Vaupel P: Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003, 55:1358-1362.
23. Vaupel P, Thews O, Mayer A, Hockel S, Hockel M: Oxygenation Status of Gynecological Tumours: What is the Optimal Haemoglobin Level? Strahlenther Onkol 2002, 178:727-731.
24. World Health Organisation: WHO handbook for reporting results of cancer treatment WHO Geneva, Switzerland; 1979.
25. Zimny M, Schröder W, Wolters S, Cremerius U, Rath W, Buell U: 18-F Fluordeoxyglukose PET beim Ovarialkarzinom: Methodik und erste Ergebnisse. Nuklearmedizin 1997, 36:228-233.